Pacific Biosciences Of California (PACB) Depreciation & Amortization (CF) (2016 - 2026)
Pacific Biosciences Of California has reported Depreciation & Amortization (CF) over the past 16 years, most recently at $2.7 million for Q4 2025.
- For Q4 2025, Depreciation & Amortization (CF) fell 4.15% year-over-year to $2.7 million; the TTM value through Dec 2025 reached $13.0 million, down 5.8%, while the annual FY2025 figure was $13.0 million, 5.8% down from the prior year.
- Depreciation & Amortization (CF) for Q4 2025 was $2.7 million at Pacific Biosciences Of California, up from $2.5 million in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $5.1 million in Q1 2025 and troughed at $1.6 million in Q2 2021.
- A 5-year average of $2.8 million and a median of $2.7 million in 2025 define the central range for Depreciation & Amortization (CF).
- On a YoY basis, Depreciation & Amortization (CF) climbed as much as 58.36% in 2025 and fell as far as 41.31% in 2025.
- Year by year, Depreciation & Amortization (CF) stood at $2.3 million in 2021, then increased by 13.61% to $2.6 million in 2022, then increased by 16.11% to $3.0 million in 2023, then fell by 3.63% to $2.9 million in 2024, then fell by 4.15% to $2.7 million in 2025.
- Business Quant data shows Depreciation & Amortization (CF) for PACB at $2.7 million in Q4 2025, $2.5 million in Q3 2025, and $2.7 million in Q2 2025.